Investigation of risk factors for the onset of glucose intolerance and thyroid disease in patients with the immune checkpoint inhibitors

Investigation of risk factors for the onset of glucose intolerance and thyroid disease in patients with the immune checkpoint inhibitors - Investigation of risk factors for the onset of glucose intolerance and thyroid disease in patients with the immune checkpoint inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026702

Enrollment

200

Registered

2017-04-25

Start date

2017-04-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melanoma, lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, The patients who received treatment of the immune checkpoint inhibitors from July 1th,2014 to March 31,2020 in Okayama university hospital. 2, The patients who were over 20 years old and could agree to be study participants voluntary. 3, Not establish the criteria of gender.

Exclusion criteria

Exclusion criteria: The patients whose ADL weakened remarkably.

Design outcomes

Primary

Measure	Time frame
The onset of glucose intolerance and thyroid function after the immune checkpoint inhibitors	—

Countries

Japan

Contacts

Public ContactJun / Mayu Eguchi/ Watanabe

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Nephrology, Rheumatology, Endocrinology and Metabolism

mayu-w@okayama-u.ac.jp086-235-7235

Outcome results